Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nautilus Biotechnology Inc (NAUT)

Nautilus Biotechnology Inc (NAUT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 331,598
  • Shares Outstanding, K 126,564
  • Annual Sales, $ 0 K
  • Annual Income, $ -59,000 K
  • EBIT $ -67 M
  • EBITDA $ -62 M
  • 60-Month Beta 1.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.87

Options Overview Details

View History
  • Implied Volatility 228.08% (-245.88%)
  • Historical Volatility 107.67%
  • IV Percentile 29%
  • IV Rank 19.58%
  • IV High 771.69% on 05/12/25
  • IV Low 95.75% on 02/09/26
  • Expected Move (DTE 15) 0.83 (31.79%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 63
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 2,089
  • Open Int (30-Day) 2,026
  • Expected Range 1.79 to 3.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +768,561.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.96 +33.67%
on 02/05/26
3.08 -14.94%
on 02/25/26
+0.54 (+25.96%)
since 02/04/26
3-Month
1.75 +49.71%
on 01/16/26
3.08 -14.94%
on 02/25/26
+0.55 (+26.57%)
since 12/04/25
52-Week
0.62 +322.58%
on 09/04/25
3.08 -14.94%
on 02/25/26
+1.41 (+116.53%)
since 03/04/25

Most Recent Stories

More News
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales

SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule proteome analysis, today announced the appointment of Amber Faust as Vice...

NAUT : 2.62 (+8.71%)
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results

SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth...

NAUT : 2.62 (+8.71%)
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026

• Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging • Commercial launch expected to initiate in late 2026,...

NAUT : 2.62 (+8.71%)
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference

SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company...

NAUT : 2.62 (+8.71%)
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report...

NAUT : 2.62 (+8.71%)
Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease

• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology  • Nautilus’ development of a single-molecule assay for...

NAUT : 2.62 (+8.71%)
Nautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay

SEATTLE, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering single-molecule proteome analysis, today announced the launch of an Early...

NAUT : 2.62 (+8.71%)
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging

• Buck Institute’s deployment of Nautilus’ instrument generates tau proteoform data, providing external validation of the company’s next-generation single-molecule proteomics platform  • Joint...

NAUT : 2.62 (+8.71%)
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results

SEATTLE, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial...

NAUT : 2.62 (+8.71%)
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025

SEATTLE, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report...

NAUT : 2.62 (+8.71%)

Business Summary

Nautilus Biotechnology Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus Biotechnology Inc., formerly known as Arya Sciences Acquisition Corp III, is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 3.00
2nd Resistance Point 2.84
1st Resistance Point 2.73
Last Price 2.62
1st Support Level 2.46
2nd Support Level 2.30
3rd Support Level 2.19

See More

52-Week High 3.08
Last Price 2.62
Fibonacci 61.8% 2.14
Fibonacci 50% 1.85
Fibonacci 38.2% 1.56
52-Week Low 0.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar